Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles.
Nanoparticles are known to accumulate in the phagocytic cells of the mononuclear phagocyte system. Therefore, the use of this carrier system for the targeting of antiviral drugs to monocytes/macrophages (MO/MAC) is an attractive concept in the treatment of diseases involving MO/MAC, e.g. infection with HIV. In this study, the ability of macrophages isolated from peripheral blood of healthy blood donors to phagocytose and metabolize human serum albumin microspheres was investigated by transmission electron microscopy. Furthermore, nanoparticles manufactured using human serum albumin or polyhexylcyanoacrylate were loaded with nucleoside analogues (AZT and ddC) and tested for their ability to prevent HIV infection in MO/MAC cultures. Our results demonstrate the effectiveness of this drug-targeting system to one of the major target cells for HIV.
Bender
A
A
Institut für Pharmazeutische Technologie d. J.W. Goethe-Universität, Frankfurt am Main, Germany.
Schfer
V
V
Steffan
A M
AM
Royer
C
C
Kreuter
J
J
Rübsamen-Waigmann
H
H
von Briesen
H
H
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D008264:Macrophages / Q000187:drug effects / Q000648:ultrastructure / Q000821:virology; D008854:Microscopy, Electron; D008863:Microspheres; D009000:Monocytes / Q000187:drug effects / Q000648:ultrastructure / Q000821:virology; D010587:Phagocytosis; D014677:Pharmaceutical Vehicles; D012709:Serum Albumin; D016047:Zalcitabine / Q000008:administration & dosage / Q000493:pharmacokinetics; D015215:Zidovudine / Q000008:administration & dosage / Q000493:pharmacokinetics
D000998:Antiviral Agents; D014677:Pharmaceutical Vehicles; D012709:Serum Albumin; D015215:Zidovudine; D016047:Zalcitabine